Literature DB >> 19654217

Validity of physician-reported hospitalized infections in a US arthritis registry.

Jeffrey R Curtis1, Nivedita M Patkar, Archana Jain, Jeffrey Greenberg, Daniel H Solomon.   

Abstract

OBJECTIVE: In safety studies, events reported as infections may be misclassified and, therefore, affect the validity of estimated risks associated with biologic agents. Using data from the Consortium of Rheumatology Researchers of North America (CORRONA), we evaluated hospitalized infection reports contributed by rheumatologists to establish their validity.
METHODS: All patients hospitalized with infections from 2002 to 2007 reported to CORRONA were examined and compared with information from hospital discharge summaries and other confirmatory data. Infectious episodes were classified by two physicians as confirmed, empirically treated, possible or unlikely.
RESULTS: Of 562 reported hospitalized infectious episodes, 9% were classified as unlikely and had minimal or no supporting evidence for infection, leaving 509 hospitalized infectious episodes. Of these, 53% of the infectious episodes were classified as confirmed, 15% empirically treated and 32% possible. The confirmation status of infectious episodes for younger or biologic-exposed participants was similar to older and biologic-unexposed participants.
CONCLUSION: More than two-thirds of hospitalized infections reported by rheumatologists were confirmed or had evidence that the physician was treating an infection. In almost all cases, there was at least modest evidence for an infection. Future studies should consider case definitions for infections or sensitivity analyses, or both, regarding the certainty of an infection to account for possible misclassification and reduce bias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654217      PMCID: PMC2744334          DOI: 10.1093/rheumatology/kep205

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.

Authors:  J R Curtis; C Martin; K G Saag; N M Patkar; J Kramer; D Shatin; J Allison; M M Braun
Journal:  Arthritis Rheum       Date:  2007-03-15

2.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.

Authors:  Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2006-12-18       Impact factor: 6.437

Review 3.  European biologicals registers: methodology, selected results and perspectives.

Authors:  A Zink; J Askling; W G Dixon; L Klareskog; A J Silman; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-07-22       Impact factor: 19.103

4.  The CORRONA database.

Authors:  J M Kremer
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

5.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

Authors:  D T Durack; A S Lukes; D K Bright
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

6.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

Authors:  Jeffrey R Curtis; Nivedita Patkar; Aiyuan Xie; Carolyn Martin; Jeroan J Allison; Michael Saag; Deborah Shatin; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2007-04

7.  Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.

Authors:  Nivedita M Patkar; Jeffrey R Curtis; Gim Gee Teng; Jeroan J Allison; Michael Saag; Carolyn Martin; Kenneth G Saag
Journal:  J Clin Epidemiol       Date:  2008-10-01       Impact factor: 6.437

  7 in total
  4 in total

1.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Authors:  Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink
Journal:  Semin Arthritis Rheum       Date:  2010-08       Impact factor: 5.532

2.  A transient peak of infections during onset of rheumatoid arthritis: a 10-year prospective cohort study.

Authors:  Marina I Arleevskaya; Aida G Gabdoulkhakova; Yulia V Filina; Regina R Miftakhova; Anders Bredberg; Anatoly P Tsybulkin
Journal:  BMJ Open       Date:  2014-09-01       Impact factor: 2.692

3.  One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Authors:  Leslie R Harrold; Heather J Litman; Katherine C Saunders; Kimberly J Dandreo; Bernice Gershenson; Jeffrey D Greenberg; Robert Low; Jeffrey Stark; Robert Suruki; Srihari Jaganathan; Joel M Kremer; Mohamed Yassine
Journal:  Arthritis Res Ther       Date:  2018-01-02       Impact factor: 5.156

4.  "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients".

Authors:  Dimitrios A Pappas; Joel M Kremer; George Reed; Jeffrey D Greenberg; Jeffrey R Curtis
Journal:  BMC Musculoskelet Disord       Date:  2014-04-01       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.